April 10, 2022

Submission Deadline Extended

3rd CFP – 2022 AsRES-AREUEA Joint Conference in Tokyo on August 4-7

Dear friends,

Trust all is well with all of you. Last week, we enjoyed cherry blossoms in full bloom which marked the beginning of the Japanese business & academic calendar that started on April 1.

We'd like to announce the Third Call for Papers of "The 26th AsRES Annual Conference: 2022 AsRES-AREUEA Joint Conference, Tokyo, Japan (hereafter AsRES 2022)" as attached.

Now, all three-time vaccinated participants who tested negative (*1, *2) - except those coming from the designated countries and regions listed below (*3) - have "basically ZERO" quarantine days upon arriving in Japan. Also, the participants can accompany people to Japan as well. (*4, *5 for quarantine periods.)
But still, all participants are supposed to apply for a visa to enter Japan. No worries! The Tokyo team will take care of preparing and sending the necessary documents once your registration is completed. (You will receive the documents within about 10-14 days after registration.)

With these improved conditions with respect to entering Japan, we'd appreciate it if you would reconsider coming to the Tokyo conference on August 4-7. With this in mind, we'd like to extend the submission deadline from April 15 to April 30. Accordingly, the notification date of accepted papers will be extended to May 20.

On the other hand, we sincerely understand that some friends prefer attending online. Of course, you are also welcome to attend the Tokyo conference online. Online participants can enjoy keynote speeches & panels via the Internet on Day 1. Also, they will present their papers on virtual-only Day 4. (We might let Day 3 be virtual-only as well, depending on the number of submissions.)

We are looking forward to having your submissions and registrations.

Please keep safe and see you soon.

Two Options to Submit Your Abstract and Paper

As AsRES 2022 will be jointly held with AREUEA, authors have two options to submit their abstract and paper.

- AsRES Only: Submit your <u>abstract by April 30</u> in order to have your paper included in AsRES sessions. If your abstract qualifies and also if you <u>submit your paper by July 4</u>, you will present at AsRES sessions.

- AREUEA-AsRES Two-Step Review: Submit your <u>full paper or a detailed abstract along with some preliminary results by April 30</u> to be considered for an AREUEA session. AREUEA will screen papers by single-blind review. If a submission is not selected for an AREUEA session, it will be automatically considered for an AsRES session.

Updated Important Dates (JST: Japan Standard Time)

April 30, 2022.   Deadline for paper or abstract submission.

May 20, 2022.   Notification of accepted papers.

Submission & Contact Information

Submission Site: https://jarefe.com/index.php/asres

Contact: areuea-tokyo2022@conftool.org

Best,

Hiroshi Ishijima, PhD

President of Asian Real Estate Society (AsRES)

Rose Neng LAI, PhD

Executive Director of Asian Real Estate Society (AsRES)

Note 1: Definition of Three-time Vaccination

(The following statements within the double quotation marks are quoted from the Japanese government URL: https://www.mhlw.go.jp/content/000903661.pdf)

The following two conditions must be satisfied:

(1) "Receive two doses from among the following vaccines (vaccine name/manufacturer):

- Comirnaty/Pfizer

- Vaxzevria/AstraZeneca

- COVID-19 Vaccine Moderna/Moderna

- Janssen COVID-19 Vaccine/Janssen

- COVAXIN／Bharat

*For the Janssen COVID-19 Vaccine/Janssen, one dose is considered equivalent to two doses.

*Doses will also be considered valid even if both are not the same vaccine.

*Regarding the application of measures based on Japan's Enhanced Border Measure (27), Comirnaty (manufactured by Fosun Pharma/BioNTech) and Covishield (manufactured by the Serum Institute of India with technology from AstraZeneca) will be treated as identical to Comirnaty/Pfizer and Vaxzevria/AstraZeneca, respectively.

* For COVAXIN／Bharat, the measures based on Japan's Enhanced Border Measure (27)will be applied from April 10th, 2022, 0:00am (Japan Time)."

(2) "Receive at a third dose, with it being one of the following vaccines (vaccine name/manufacturer):

- Comirnaty/Pfizer

- COVID-19 Vaccine Moderna/Moderna

* Regarding the application of measures based on Japan's Enhanced Border Measure (27), Comirnaty (manufactured by Fosun Pharma/BioNTech) will be treated as identical to Comirnaty/Pfizer."

Note 2: Inspection Certificate

(The statements within the double quotation marks are quoted from the Japanese government URL: https://www.mhlw.go.jp/stf/covid-19/bordercontrol.html)

"All entrants must provide a certificate of inspection within 72 hours prior to departure. If you are unable to present the certificate, you will not be allowed to land in Japan based on the Quarantine Law."

Note 3: Designated Countries and Regions

As of April 7, 2022, designated countries/regions are: 1) All of Russia, 2) Turkey, 3) Sri Lanka, 4) Republic of Korea, 5) Egypt, 6) Pakistan, 7) Vietnam.

The list is quoted from the table provided by the Japanese government: https://www.mhlw.go.jp/content/000883267.xlsx

Note 4: Quarantine Periods for the Participants from Non-Designated Countries/Regions

-Booster vaccinated: Not required any self-quarantine.

-Booster unvaccinated: 3 days self-quarantine at your home ＋COVID-19 test negative or 7 days self-quarantine without COVID-19 test.

Reference URL: https://www.mhlw.go.jp/stf/covid-19/bordercontrol.html

Quarantine Guideline: https://www.mhlw.go.jp/content/000903661.pdf

Note 5: Quarantine Periods for the Participants from Designated Countries/Regions

-Booster vaccinated: 3 days self-quarantine at your home ＋ COVID-19 test negative. or 7 days self-quarantine without COVID-19 test.

-Booster unvaccinated: 3 days self-quarantine at the facilities designated by the quarantine station ＋ COVID-19 test negative.

Reference URL: https://www.mhlw.go.jp/stf/covid-19/bordercontrol.html

Quarantine Guideline: https://www.mhlw.go.jp/content/000903661.pdf